Brought to you by 
Neose, Neuronyx to develop drugs for Parkinson's disease
21 Dec 2000
Executive Summary
Neuronyx, a new biotech company developing drugs for brain and CNS disorders, signed its first deal with Neose Technologies (complex carbohydrates) to develop glycolipid compounds to treat Parkinson's disease and other neurological disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neose, Neuronyx to develop drugs for Parkinson's disease
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice